Treos Bio updates results of phase 1/2 trial of its cancer vaccine
Category: #health  By Paroma Bhattacharya  Date: 2019-09-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Treos Bio updates results of phase 1/2 trial of its cancer vaccine

Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient).

Treos Bio Ltd. has reportedly updated positive outcomes on the second segment of phase 1/2 trial (OBERTO) along with PolyPEPI1018 cancer injection. The second part of the trial is a supplement to the company’s maintenance treatment in patients suffering from microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Apparently, the phase 1/2 study is a single-arm, open-label, multicenter trial. The trial aims to evaluate the tolerability, safety, preliminary efficacy, and immunogenicity of single dose or multiple doses of PolyPEPI1018. The doses are intended as a supplement to maintenance treatment in subjects suffering from metastatic colorectal cancer following the first-line induction chemotherapy. Initial outcomes from the first part of the trial were exhibited at ASCO 2019 and outcomes of the second part have been made available now.

Reportedly, patients with mCRC in first line setting were given up to three dosages of PolyPEPI1018 vaccine (0.2 mg/peptide) 12 weeks apart. Doses were given following the transition to maintenance treatment with bevacizumab and fluoropyrimidine. Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient). Later, these responses were calculated after one series of vaccination.

Joleen M. Hubbard, M.D., principal investigator of the OBERTO study, Mayo Clinic, reportedly stated that in addition to the unforeseen tumor responses examined for a few of the patients, it has been very reassuring that most of the subjects on multiple doses controlled their disorder till the completion of the follow-up time and beyond. The investigators have planned to continue registration of more patients in the trial and follow them for an even extended interval this time, she further added.

Reports confirm that in addition to the presentation of poster of the OBERTO study outcomes, three more posters will be displayed by Treos Bio at ESMO 2019. Those extra posters will be associated with its PEPI based platform technology and science.

Source credits:

https://finance.yahoo.com/news/treos-bio-reports-updated-positive-091500643.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...

Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
Genentech IMbrave150 study meets coprimary endpoints for HCC treatment
By Paroma Bhattacharya

With growing occurrence of liver cancer cases across the globe, the need to find a solution to the ailment is rising steadily among global biotechnology and pharmaceutical firms. Various clinical trials and studies are...

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
By Paroma Bhattacharya

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis ...